Bruno Lafont co-founded NFL Biosciences in 2009, and is in charge of the structuring and technical development of NFL Biosciences and its various projects. Previously, Bruno spent 12 years on the management team of PCM, an international French industrial group, as Innovation Director from 1999 to 2004, then as President and in charge of setting up the group's US subsidiary in Houston (Texas) from 2004 to 2009. Bruno holds an engineering degree in biochemistry from the Institut National des Sciences Appliquées (INSA) in Toulouse, a Master's degree in management from EMLyon, and an Executive MBA from the Ecole Polytechnique Fédérale de Lausanne and HEC Lausanne.

Dr. Ignacio Faus joined NFL Biosciences in 2019 as an investor, then the management team in early 2021. Dr. Ignacio Faus has 27 years' experience in large and medium-sized pharmaceutical companies, as well as in private and listed biotech companies: Bristol Myers Squibb, Grupo Uriach, Ferrer and co-founder in 2006 and Managing Director of Palau Pharma (sold in 2013). In recent years, Ignacio Faus has also been a director of several private and listed biotech companies and private equity funds in Europe and the United States. Ignacio holds a PhD in Biochemistry (Indiana University, USA) and an MBA in Entrepreneurship and Finance from the Kellogg School of Management (Northwestern University, USA).

Guillaume Audema joined NFL Biosciences' Finance Department at the beginning of 2022. Guillaume spent 7 years with the international firms KPMG and then PWC, working on audit and advisory assignments in the organizational and financial fields for companies of all sizes, notably listed on the French and American financial markets. Before joining the team, he spent 3 years on a financial structuring assignment for an SME. Guillaume holds a Master's degree in Accounting and Controlling from the University of Montpellier and a Diplôme Supérieur de Comptabilité et de Gestion.